Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00004029
First received: December 10, 1999
Last updated: February 8, 2013
Last verified: June 2006

December 10, 1999
February 8, 2013
December 1996
May 2006   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00004029 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer
A PHASE I TRIAL OF RECOMBINANT VACCINIA VIRUS THAT EXPRESSES PSA IN PATIENTS WITH ADENOCARCINOMA OF THE PROSTATE

Phase I trial to study the effectiveness of vaccine therapy in treating patients with metastatic prostate cancer. Vaccines may make the body build an immune response to kill tumor cells.

OBJECTIVES:

I. Assess the toxicity associated with repeated vaccination with recombinant vaccinia virus expressing prostate-specific antigen (rV-PSA) in patients with metastatic adenocarcinoma of the prostate.

II. Determine the optimal dose of rV-PSA given at monthly intervals based on cellular and hormonal immunity.

III. Determine whether vaccination with rV-PSA is associated with anti-tumor activity.

IV. Determine whether granulocyte-macrophage colony-stimulating factor (GM-CSF) has an effect on cellular and humoral immunity different from rV-PSA, and whether the addition of GM-CSF has enhanced antitumor effect compared to rV-PSA alone.

OUTLINE: This is an open label, dose escalation study.

Patients in cohorts of 3-6 receive 3 vaccinations with rV-PSA at 4-week intervals (days 1, 29, 57, and 85) in the absence of disease progression or unacceptable toxicity. Response assessment is performed at eight weeks. Patients who discontinue therapy prior to eight weeks are considered unevaluable for response. If dose limiting toxicity is observed in 2 of 6 patients entered at a dose level, no further patients are entered at that level and the MTD is defined as the preceding dose level. Ten additional patients are treated at the MTD and receive granulocyte-macrophage colony-stimulating factor (GM-CSF) administered subcutaneously on day -1 through day 2 of each cycle. Patients who are HLA-A2 positive, have received all 3 rV-PSA vaccinations without unacceptable toxicity, and have been off study for at least 30 days due to disease progression may continue treatment with rV-PSA at the highest dose level and the addition of GM-CSF.

Patients are followed monthly for 6 months.

Interventional
Phase 1
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Prostate Cancer
  • Biological: recombinant viral vaccine therapy
  • Biological: sargramostim
Experimental: Arm I
atients in cohorts of 3-6 receive 3 vaccinations with rV-PSA at 4-week intervals (days 1, 29, 57, and 85) in the absence of disease progression or unacceptable toxicity. Response assessment is performed at eight weeks. Patients who discontinue therapy prior to eight weeks are considered unevaluable for response. If dose limiting toxicity is observed in 2 of 6 patients entered at a dose level, no further patients are entered at that level and the MTD is defined as the preceding dose level. Ten additional patients are treated at the MTD and receive granulocyte-macrophage colony-stimulating factor (GM-CSF) administered subcutaneously on day -1 through day 2 of each cycle. Patients who are HLA-A2 positive, have received all 3 rV-PSA vaccinations without unacceptable toxicity, and have been off study for at least 30 days due to disease progression may continue treatment with rV-PSA at the highest dose level and the addition of GM-CSF.
Interventions:
  • Biological: recombinant viral vaccine therapy
  • Biological: sargramostim
  • Eder JP Jr, Kantoff PW, Bubley GJ, et al.: A phase I trial of recombinant prostate specific antigen expressing vaccinia virus vaccine, PROSTVAC (rV-PSA) in advanced prostate cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 18: A1692, 439, 1999.
  • Eder JP Jr, Kantoff PW, Bubley GJ, et al.: A phase I trial of recombinant vaccinia virus, PROSTVAC that expresses prostate specific antigen (rV-PSA) as a vaccine in men with advanced prostate cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 17: A1672, 434, 1998.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
46
Not Provided
May 2006   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Histologically proven adenocarcinoma of the prostate with evidence of metastatic disease based on any of the following:

    • Lymph node positive and PSA at least 10 ng/mL
    • Bone scan positive and PSA at least 10 ng/mL
    • PSA at least 2 ng/mL and rising following radical prostatectomy
    • PSA at least 10 ng/mL following radiotherapy
  • No symptomatic metastatic disease (bony pain)

PATIENT CHARACTERISTICS:

  • Age: 18 and over
  • Performance status: ECOG 0 or 1
  • WBC greater than 2,000/mm3
  • Platelet count greater than 100,000/mm3
  • Bilirubin less than 2.0 mg/dL
  • AST less than 4 times normal
  • Creatinine less than 2.0 mg/dL
  • Must be type HLA-A2 Prior vaccinia (smallpox) exposure required
  • At least normal delayed type hypersensitivity to mumps and Candida
  • At least normal CD4:CD8 ratio (greater than 1)
  • At least normal lymphocyte proliferation testing (to Con A)
  • At least normal immunoglobulin levels
  • No evidence of altered immune responsiveness or autoimmune syndromes (e.g., scleroderma, systemic lupus erythematosus)
  • No HIV antibody No prior splenectomy
  • No known allergy to eggs
  • No active extensive skin disorders (e.g, psoriasis, burns, impetigo, disseminated zoster)
  • No other serious intercurrent illness
  • No active infections unless cleared and at least 3 days since antibiotic therapy
  • No close contact for 2 weeks after each vaccination with the following people:

    • Children less than 3 years old
    • Pregnant women
    • Individuals with eczema or skin conditions listed above
    • Immunosuppressed individuals

PRIOR CONCURRENT THERAPY:

  • No concurrent biologic therapy
  • No prior chemotherapy for metastatic disease
  • No prior hormone therapy for metastatic disease
  • Neoadjuvant hormone therapy prior to prostatectomy or radiotherapy allowed
  • No concurrent steroids or hormonal medications
  • Prior radiotherapy allowed
  • Prior surgery allowed
Male
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00004029
CDR0000065275, DFCI-96079, NCI-T95-0086H
Not Provided
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Not Provided
Study Chair: Donald W. Kufe, MD Dana-Farber Cancer Institute
National Cancer Institute (NCI)
June 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP